Mydriatic Eyedrops Market Scope
The mydriatic eyedrops are the part of a mydriatic line of medicines that helps in treating the Mydriasis, the eyedrops make the pupil of the eye wide open (dilate). The mydriatics are also used to treat inflammatory eye conditions such as cyclitis, iritis and also it reduces painful paralysis of the ciliary muscle of the eye (cycloplegia). The mydriatic eyedrops such as tropicamide relax the iris sphincter which is innervated by the parasympathetic nervous system. There are also various types of mydriatics available such as phenylephrine, atropine, mydrilate, homatropine and mydriacyl.
The market study is being classified by Type (Atropine, Mydrilate (Cyclopentolate), Homatropine, Mydriacyl (Tropicamide) and Phenylephrine), by Application (Infants, Children and Adults) and major geographies with country level break-up.
Novartis AG (Switzerland), Alcon Laboratories (M) Sdn Bhd (Malaysia), Santen Pharmaceutical Co., Ltd. (Japan), Visine (Johnson & Johnson Consumer Inc.) (United States), Akorn Inc. (United States), Hikma Pharmaceuticals (United Kingdom), Fresenius Kabi (Germany), Cipla Limited (India), Ocuphire Pharma, Inc. (United States), Eyekare Kilitch Ltd. (India) and MOLBASE (Shanghai) Biotechnology Co., Ltd (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Manus Aktteva Biopharma LLP (India) and Iwaki Seiyaku Co., Ltd (Japan).
AdvanceMarketAnalytics has segmented the market of Global Mydriatic Eyedrops market by Type, Application and Region.
On the basis of geography, the market of Mydriatic Eyedrops has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 1st April 2019, Alcon announced the expansion of Alcaine (proparacaine hydrochloride ophthalmic solution, USP) 0.5% 15mL to its Procedural Eye Drops portfolio, which is made up of mydriatic, cycloplegic, diagnostic and anesthetic products. Alcaine Solution 0.5% 15mL, the only branded proparacaine available, is a topical local anesthetic indicated for corneal anesthesia of short duration, and for short corneal and conjunctival procedures. They offer a complete line of high-quality ophthalmic products to customers. Alcaine Solution 0.5% 15mL has been a trusted solution for surgical and clinical ophthalmic procedures. We hope by offering this product directly from Alcon we will continue to meet the ongoing needs of patients and eye care professionals.
- Increasing Number of Licence Approvals for Mydriatic Medicines
- Continuous Research in Mydriatic Eyedrop Products
- Growing Number of Genetic Mydriasis Cases to Children
- Increasing Issues Due to Chemical Injuries or Wound on Eyes Leading to Dilated Pupils
- Growing Online Sales Channels will Boost the Mydriatic Eyedrops Market
- Surging Availability of Mydriatic Eyedrops in Online Channels
- Side Effects Associated with Mydriatic Eyedrops
- Regulatory Standards on Mydriatic Eyedrops
- Proper Labeling and Packaging Mydriatic Eyedrops for Effective Use
Key Target AudienceMydriatic Eyedrops Manufacturers, Mydriatic Eyedrops International Traders, Mydriatic Eyedrops Distributors and Suppliers, Research and Development Institutes, Potential Investors, Industry Associations, Upstream and Downstream Buyers, Regulatory Bodies and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase